Valeo Financial Advisors LLC increased its stake in Eli Lilly And Co (NYSE:LLY) by 11.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,697 shares of the company’s stock after acquiring an additional 5,213 shares during the period. Eli Lilly And Co makes up approximately 0.8% of Valeo Financial Advisors LLC’s investment portfolio, making the stock its 19th biggest position. Valeo Financial Advisors LLC’s holdings in Eli Lilly And Co were worth $6,578,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Nachman Norwood & Parrott Inc boosted its holdings in Eli Lilly And Co by 0.8% during the first quarter. Nachman Norwood & Parrott Inc now owns 14,877 shares of the company’s stock worth $1,930,000 after buying an additional 119 shares in the last quarter. Gradient Investments LLC boosted its holdings in Eli Lilly And Co by 255.2% during the first quarter. Gradient Investments LLC now owns 2,618 shares of the company’s stock worth $340,000 after buying an additional 1,881 shares in the last quarter. Lake Street Financial LLC bought a new stake in Eli Lilly And Co during the first quarter worth approximately $529,000. Handelsinvest Investeringsforvaltning bought a new stake in Eli Lilly And Co during the first quarter worth approximately $411,000. Finally, Moody National Bank Trust Division boosted its holdings in Eli Lilly And Co by 0.4% during the first quarter. Moody National Bank Trust Division now owns 131,015 shares of the company’s stock worth $17,000,000 after buying an additional 500 shares in the last quarter. Institutional investors and hedge funds own 79.58% of the company’s stock.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 51,766 shares of the stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $117.74, for a total value of $6,094,928.84. Following the completion of the sale, the insider now owns 117,963,538 shares in the company, valued at approximately $13,889,026,964.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Aarti S. Shah sold 1,800 shares of the stock in a transaction that occurred on Friday, April 5th. The stock was sold at an average price of $125.85, for a total transaction of $226,530.00. Following the completion of the sale, the senior vice president now owns 18,425 shares of the company’s stock, valued at approximately $2,318,786.25. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,040,990 shares of company stock valued at $129,682,182. 0.11% of the stock is owned by insiders.

Shares of NYSE:LLY opened at $123.06 on Monday. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38. The company has a market capitalization of $129.63 billion, a P/E ratio of 22.17, a PEG ratio of 2.37 and a beta of 0.33. Eli Lilly And Co has a 52 week low of $77.09 and a 52 week high of $132.13.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). The firm had revenue of $6.44 billion during the quarter, compared to analysts’ expectations of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The firm’s revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.14 EPS. On average, research analysts expect that Eli Lilly And Co will post 5.66 earnings per share for the current year.

A number of analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 target price for the company in a report on Wednesday, April 10th. Barclays restated a “buy” rating and set a $140.00 target price on shares of Eli Lilly And Co in a report on Sunday. Guggenheim cut shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 target price for the company. in a report on Thursday. Credit Suisse Group set a $121.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a report on Friday, March 22nd. Finally, UBS Group assumed coverage on shares of Eli Lilly And Co in a report on Wednesday, March 20th. They set a “buy” rating and a $74.51 target price for the company. Ten analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $118.02.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2019/04/15/eli-lilly-and-co-lly-stake-lifted-by-valeo-financial-advisors-llc.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: How to invest in a bear market

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.